—
The report provides comprehensive information on the therapeutics under development for Grass Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects.Get Sample Report @ https://www.wiseguyreports.com/sample-request/413794-grass-pollen-allergy-pipeline-review-h1-2016
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy
- The report reviews pipeline therapeutics for Grass Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Grass Pollen Allergy therapeutics and enlists all their major and minor projects
- The report assesses Grass Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Grass Pollen Allergy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Grass Pollen Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Grass Pollen Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Grass Pollen Allergy Overview 7
Therapeutics Development 8
Pipeline Products for Grass Pollen Allergy - Overview 8
Grass Pollen Allergy - Therapeutics under Development by Companies 9
Grass Pollen Allergy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Grass Pollen Allergy - Products under Development by Companies 13
Grass Pollen Allergy - Companies Involved in Therapeutics Development 14
ALK-Abello A/S 14
Allergy Therapeutics Plc 15
Anergis SA 16
Biomay AG 17
Circassia Pharmaceuticals Plc 18
HAL Allergy BV 19
Roxall Medizin GmbH 20
Shionogi & Co., Ltd. 21
Grass Pollen Allergy - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
AllerG - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Allergen for Grass Allergy - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
asapiprant - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
BM-32 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
clustoid wiesenlieschgras - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Pollinex Quattro Grass - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Grass Pollen Allergy - Recent Pipeline Updates 43
Grass Pollen Allergy - Dormant Projects 50
Grass Pollen Allergy - Product Development Milestones 51
Featured News & Press Releases 51
Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL 51
Access Report @ https://www.wiseguyreports.com/reports/413794-grass-pollen-allergy-pipeline-review-h1-2016
Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
Contact Info:
Name: Norah Trent
Email: Send Email
Organization: WiseGuy Reports
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349
Website: http://www.wiseguyreports.com
Release ID: 144949
Google
RSS